Last reviewed · How we verify

Fine Wrinkling — Treatment Landscape & Competitive Intelligence

Fine Wrinkling (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Fine Wrinkling, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Retin-A TRETINOIN Bausch Health Retinoid [EPC] Nuclear receptor ROR-beta 1971-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bausch Health · 1 drug in Fine Wrinkling

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Fine Wrinkling:

Cite this brief

Drug Landscape (2026). Fine Wrinkling — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/fine-wrinkling. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing